

**REDX PHARMA PLC**  
**("Redx" or "the Company")**

**Result of Annual General Meeting and Directorate change**

**Alderley Park, 2 March 2021** Redx Pharma (AIM:REDX), the drug discovery and development Company focused on oncology and fibrosis, today announces that its Annual General Meeting was held at 11.00 am on 2 March 2021, with all resolutions passed by substantial majorities.

The table below sets out the details of the votes put to shareholders

Resolution number	Resolution name	Number of votes for & discretionary	% of votes for & discretionary	Number of votes against	% of votes against	% of votes withheld	Total votes cast (including withheld)
1	Receive the Company's annual accounts	247,031,884	94.79%	13,571,429	5.21%	0.00%	260,604,013
2	Re-appoint RSM as auditors	260,597,840	100%	200	0.00%	0.00%	260,604,013
3	Elect Sarah Gordon Wild as a director	260,597,840	100%	200	0.00%	0.00%	260,604,013
4	Elect Dr Thomas Burt as a director	260,597,840	100%	200	0.00%	0.00%	260,604,013
5	Re-elect Lisa Anson as a director	260,603,513	100%	0	0.00%	0.00%	260,604,013
6	Re-elect Dr Bernd Kirschbaum as a director	260,598,040	100%	0	0.00%	0.00%	260,604,013
7	Re-elect Peter Presland as a director	260,603,513	100%	0	0.00%	0.00%	260,604,013
8	Authorise the directors to allot shares	260,594,551	100%	1,686	0.00%	0.00%	260,604,013
9	Disapply pre-emption rights	260,594,551	100%	2,389	0.00%	0.00%	260,604,013

The Chairman, Iain Ross provided the following update:

"As the Company continues to progress its pipeline and expand its operations, the Board has reviewed its composition and that of the executive leadership team. As a result, a search for a US based Chief Financial Officer has been initiated. James Mead will continue in his role as Chief Financial Officer until a new appointment has been made at which point Dr Mead will assume the role of Chief Operating Officer. In conjunction with these changes, Dr Mead will step down from the Board with immediate effect and will cease to be a Director of the Company. Going forward, the Board will therefore consist of five non-executive directors and one executive director, the CEO. Finally on a personal basis I would like to thank James for his contribution to the Board over the last two years, and his ongoing commitment as a member of the executive management team going forward."

**For further information, please contact:**

**Redx Pharma Plc**

Iain Ross, Chairman  
 Lisa Anson, Chief Executive  
 James Mead, Chief Financial Officer

**T: +44 1625 469 918**

**SPARK Advisory Partners (Nominated Adviser)**

Matt Davis/Adam Dawes

**T: +44 203 368 3550**

**WG Partners LLP (Broker)**

Claes Spång/Chris Lee/David Wilson

**T: +44 20 3705 9330**

**FTI Consulting**

**T: +44 20 3727 1000**

Simon Conway/Ciara Martin

**About Redx Pharma Plc**

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx's lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.

The Company's core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGUUOURANUORAR